Recombinant adeno-associated virus-mediated human kallikrein gene therapy prevents high-salt diet-induced hypertension without effect on basal blood pressure

[1] Chobanian AV(2003)The seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure: The JNC 7 report. JAMA 289 2560-2

[2] Bakris GL(2000)Effects of ACE inhibitors, calcium antagnosists, and other blood-pressure-lowering drugs. Lancet 356 1955-64

[3] Black HR(2001)Gene therapy for hypertension: the preclinical data. Hypertension 38 543-8

[4] Cushman WC(1998)Production of high-titer recombinant adenoassociated virus vectors in the absence of helper virus. J Virol 72 2224-32

[5] Green LA(2000)Overcoming adeno-associated virus vector size limitation through viral DNA heterodimerization. Nat Med 6 599-602

[6] Izzo JL(2000)AAV: is clinical success in the horizon? Gene Therapy 7 24-30

[7] Neal B(1992)Bioregulation of kinins: kallikreins, kininogens, kininases. Pharmacol Rev 44 1-8

[8] Macmahon S(2005)Kallikrein-kinin in stroke, cardiovascular and renal diseases. Exp Physiol 90 291-8

[9] Chapman N(2004)Recombinant adeno-associated virus-mediated kallikrein gene therapy reduces hypertension and attenuates its cardiovascular injuries. Gene Ther 11 1342-50

[10] Phillips MI(1996)Salt sensitivity of blood pressure in humans. Hypertension 27 481-90

[1] Chobanian AV(2003)The seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure: The JNC 7 report. JAMA 289 2560-2

[2] Bakris GL(2000)Effects of ACE inhibitors, calcium antagnosists, and other blood-pressure-lowering drugs. Lancet 356 1955-64

[3] Black HR(2001)Gene therapy for hypertension: the preclinical data. Hypertension 38 543-8

[4] Cushman WC(1998)Production of high-titer recombinant adenoassociated virus vectors in the absence of helper virus. J Virol 72 2224-32

[5] Green LA(2000)Overcoming adeno-associated virus vector size limitation through viral DNA heterodimerization. Nat Med 6 599-602

[6] Izzo JL(2000)AAV: is clinical success in the horizon? Gene Therapy 7 24-30

[7] Neal B(1992)Bioregulation of kinins: kallikreins, kininogens, kininases. Pharmacol Rev 44 1-8

[8] Macmahon S(2005)Kallikrein-kinin in stroke, cardiovascular and renal diseases. Exp Physiol 90 291-8

[9] Chapman N(2004)Recombinant adeno-associated virus-mediated kallikrein gene therapy reduces hypertension and attenuates its cardiovascular injuries. Gene Ther 11 1342-50

[10] Phillips MI(1996)Salt sensitivity of blood pressure in humans. Hypertension 27 481-90